All News

The National Alliance of Healthcare Purchaser Coalitions releases resources for employers/health plan purchasers to offer insights on PBMs role in high prescription drug costs.

NORD goes on record that IRA’s MDPNP will lead to stifling of innovation for rare disease community.

The confirmatory study—which tracked 18 months of data—helped clear the way for new Alzheimer’s drug.

Newly-issued final guidance focuses on language used when communicating quantitative efficacy or risk information.

Service expected to help companies discover partners in funding.

Partnership to focus on developing immunotherapies for patients with cancer.

Complaints filed against CMS target the unconstitutionality of the Act, while the stifling of innovation in biopharma runs a parallel argument for numerous reasons

The collaboration will use results-based financing to achieve its goals.

Indicates that reimbursement for new slate of Alzheimer’s treatments will occur only with the completion of studies to support full approval.

Agency hopes to update and improve its advisory committee composition and operations—to help FDA scientists “get the best advice possible.”

Amid drug pricing blame game, Congress advancing a range of reform efforts to manage and curb pharmacy benefit manager practices.

The UK BioIndustry Association and Clarivate detail current economic trends in the UK Biotech Financing Report.

Agency hopes to attract more seasoned expertise in manufacturing; also looking to add field inspectors.

Janssen, Johns Hopkins Dermatology’s Ethnic Skin Fellowship Program partnership focuses on improving clinical care and advancing research for skin-of-color patients.

Amid continued tussling over drug costs, a new working group will review the government’s authority to revoke licenses for medical products.

Pending FDA approval, agreement expected to support once-daily stimulant medication.

Silicon Valley Bank has collapsed, leaving many biotechnology companies unsure of the future.

Manufacturer to withdraw preterm birth drug, amid latest FDA push.

Latest investigation signals more scrutiny of pharmacy benefit managers and their role in treatment cost and coverage.

The platform is designed to reduce barriers to care for patients with COVID-19.

In its ninth year, the survey includes the opinions of over 240 US-based patient groups on the performance of the pharmaceutical industry in 2021.

The HBA announced the 2023 Woman of the Year, Honorable Mentor, and STAR recipients.

The report highlights various treatments for HIV, Parkinson's disease, Crohn's disease, alopecia, multiple myeloma, and breast cancer.

The FDA tapped the Reagan-Udall Foundation to launch the initiative.

The International Federation of Pharmaceutical Manufacturers and Associations commissioned Ipsos to perform the research.

This is the intelligence company's fifth acquisition.

Nearly 7,000 researchers from across the globe received designations.

Life sciences professionals will need to keep up with market demand for biologics and biosimilars.

Deeper focus on patient engagement across the pharma/biotech product lifecycle.